ClinicalTrials.gg

Program

abrysvo

Also written as “RSVpreF”, “RSVpreF Vaccine” and “RSVpreF (Regimen A)”.

Its studies are mostly in Respiratory Tract Infections · Respiratory Syncytial Virus Infections · COVID-19 · Influenza, Human, led by 2 companies.

Furthest: phase 3, since Jun 3, 202018 company-led studies, 7 open or runningNext primary completion: Jan 18, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer177 open or runningphase 3since Jun 3, 2020Jun 3, 2020Jan 18, 2027phase 3 · NCT05035212
Hvivo10 open or runningphase 2since Feb 12, 2021Feb 12, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Jun 3, 2020.

  1. Aug 20, 2021Phase 3 study in Lower Respiratory Tract IllnessPfizer · NCT05035212 · 38,861 enrolled · United States, Argentina, Canada and more
  2. Oct 14, 2021Phase 3 study in RSVPfizer · NCT05096208 · 1,028 enrolled · United States
  3. Mar 3, 2023Phase 1 study in Influenza, HumanPfizer · NCT05788237 · 508 enrolled · Argentina
  4. Apr 24, 2023Phase 3 study in RESPIRATORY SYNCYTIAL VIRUS (RSV)Pfizer · NCT05842967 · 885 enrolled · United States
  5. May 31, 2023Phase 2 study in COVID-19Pfizer · NCT05886777 · 1,142 enrolled · United States
  6. Jun 2, 2023Phase 1 study in Respiratory Tract InfectionsPfizer · NCT05900154 · 128 enrolled · United States
  7. Mar 8, 2024Phase 3 study in Respiratory Tract InfectionsPfizer · NCT06325657 · 681 enrolled · South Africa
  8. Sep 9, 2024Phase 3 study in Respiratory Tract InfectionsPfizer · NCT06593587 · 378 enrolled · South Korea
  9. Mar 4, 20252 phase 3 studiesPfizer · NCT06866405, NCT06890416
  10. Apr 15, 2026Phase 3 study in Respiratory Syncytial Virus (RSV)Pfizer · NCT07543380 · 130 enrolled · Japan
  11. Jun 11, 2026Phase 3 study in Respiratory Syncytial Virus (RSV)Pfizer · NCT07653100 · 540 planned · India
  12. Aug 12, 2026Phase 3 study in Respiratory Syncytial Virus (RSV)Pfizer · NCT07768345 · 440 planned · United States
  13. Sep 8, 20262 phase 3 studiesPfizer · NCT07819097, NCT07839871
  14. Oct 14, 2026Phase 3 study in Respiratory Syncytial Virus (RSV)Pfizer · NCT07885956 · 750 planned

Ahead

  1. Jan 18, 2027Primary completion: phase 3 study in Lower Respiratory Tract IllnessPfizer · NCT05035212
  2. Jan 25, 2027Primary completion: phase 3 study in Respiratory Syncytial Virus (RSV)Pfizer · NCT07653100
  3. May 16, 2027Primary completion: phase 3 study in AdultPfizer · NCT07819097
  4. Feb 2, 2028Primary completion: phase 3 study in Respiratory Syncytial Virus (RSV)Pfizer · NCT07768345

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Fusion glycoprotein F0 vaccine antigen”ChEMBL 37, by rule

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07885956Respiratory Syncytial Virus (RSV)3Not yet recruitingPfizerFeb 7, 2029750
NCT07839871Respiratory Syncytial Virus (RSV) · United States, Japan, Poland and more3RecruitingPfizerMar 30, 2031920
NCT07819097Adult · United States, China3RecruitingPfizerMay 16, 2027600
NCT07768345Respiratory Syncytial Virus (RSV) · United States3RecruitingPfizerFeb 2, 2028440
NCT07653100Respiratory Syncytial Virus (RSV) · India3RecruitingPfizerJan 25, 2027540
NCT07543380Respiratory Syncytial Virus (RSV) · Japan3CompletedPfizerAug 25, 2026130
NCT06890416Respiratory Syncytial Virus (RSV) · United States, Puerto Rico3CompletedPfizerSep 30, 2025526
NCT06866405Respiratory Syncytial Virus Infections · United States, Argentina, South Africa and more3RecruitingPfizerFeb 24, 2028550
NCT06593587Respiratory Tract Infections · South Korea3CompletedPfizerFeb 3, 2025378
NCT06325657Respiratory Tract Infections · South Africa3CompletedPfizerJun 11, 2025681
NCT05900154Respiratory Tract Infections · United States1CompletedPfizerFeb 29, 2024128
NCT05886777COVID-19 · United States2CompletedPfizerJan 1, 20241,142
NCT05842967RESPIRATORY SYNCYTIAL VIRUS (RSV) · United States3CompletedPfizerMar 18, 2024885
NCT05788237Influenza, Human · Argentina1CompletedPfizerSep 27, 2023508
NCT05096208RSV · United States3CompletedPfizerApr 4, 20221,028
NCT05035212Lower Respiratory Tract Illness · United States, Argentina, Canada and more3Active, not recruitingPfizerJan 18, 202738,861
NCT04785612Respiratory Syncytial Virus Infections · United Kingdom2CompletedHvivoApr 8, 202170
NCT04424316Respiratory Tract Infections · United States, Argentina, Australia and more3CompletedPfizerOct 27, 202314,727

How it is read

Names in the registry

  • “RSVpreF”, 10 entries
  • “RSVpreF Vaccine”, 2 entries
  • “RSVpreF (Regimen A)”, 1 entry
  • “RSVpreF (Regimen B)”, 1 entry
  • “RSVpreF vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.